Trial did not meet primary endpoint of statistically significant rate of change in GA lesion area using slope analysis over 52 weeks for NGM621 versus sham
NGM621 showed favorable safety and tolerability, with no evidence of increased CNV conversion and no treatment-related SAEs
Additional analyses to be presented in early November at The Retina Society Annual Scientific Meeting
NGM Bio to host conference call and webcast today at 8:00 a.m. ET
NGM Bio will host a conference call and webcast with slide presentation at 8:00 a.m. ET (5:00 a.m. PT) today. To access the live webcast and slides, please visit the “Investors & Media” section of NGM Bio’s website at https://ir.ngmbio.com/. The webcast will be archived for 30 days.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.